tradingkey.logo

Cumberland Pharmaceuticals Inc

CPIX
4.410USD
+0.030+0.68%
Close 12/19, 16:00ETQuotes delayed by 15 min
65.96MMarket Cap
LossP/E TTM

Cumberland Pharmaceuticals Inc

4.410
+0.030+0.68%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Cumberland Pharmaceuticals Inc

Currency: USD Updated: 2025-12-19

Key Insights

Cumberland Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 77/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cumberland Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
77 / 158
Overall Ranking
192 / 4582
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cumberland Pharmaceuticals Inc Highlights

StrengthsRisks
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.87M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 37.87M.
Undervalued
The company’s latest PE is -19.06, at a low 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 515.47K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-19

The current financial score of Cumberland Pharmaceuticals Inc is 7.87, ranking 93/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 8.29M, representing a year-over-year decrease of 8.73%, while its net profit experienced a year-over-year decrease of 25.69%.

Score

Industry at a Glance

Previous score
7.87
Change
0

Financials

7.55

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

6.62

Operational Efficiency

10.00

Growth Potential

7.90

Shareholder Returns

7.30

Cumberland Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-12-19

The current valuation score of Cumberland Pharmaceuticals Inc is 8.81, ranking 6/158 in the Pharmaceuticals industry. Its current P/E ratio is -19.06, which is -92.73% below the recent high of -1.39 and -29.45% above the recent low of -24.68.

Score

Industry at a Glance

Previous score
8.81
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 77/158
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-19

The current earnings forecast score of Cumberland Pharmaceuticals Inc is 6.00, ranking 130/158 in the Pharmaceuticals industry.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Cumberland Pharmaceuticals Inc
CPIX
1
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-19

The current price momentum score of Cumberland Pharmaceuticals Inc is 9.72, ranking 2/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 5.34 and the support level at 2.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.74
Change
-0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.536
Buy
RSI(14)
84.118
Overbought
STOCH(KDJ)(9,3,3)
91.029
Overbought
ATR(14)
0.392
High Vlolatility
CCI(14)
149.252
Buy
Williams %R
6.348
Overbought
TRIX(12,20)
1.787
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
3.844
Buy
MA10
3.117
Buy
MA20
2.658
Buy
MA50
2.747
Buy
MA100
3.023
Buy
MA200
3.754
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-19

The current institutional shareholding score of Cumberland Pharmaceuticals Inc is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 28.11%, representing a quarter-over-quarter increase of 0.00%. The largest institutional shareholder is James Simons, holding a total of 515.47K shares, representing 3.45% of shares outstanding, with 2.43% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Kazimi (A J)
5.70M
+0.00%
Millennium Management LLC
775.98K
-4.19%
Ikarian Capital LLC
595.93K
-19.47%
Renaissance Technologies LLC
Star Investors
494.96K
-1.67%
The Vanguard Group, Inc.
Star Investors
411.79K
-1.15%
Krogulski (Kenneth J)
291.03K
+0.45%
Dimensional Fund Advisors, L.P.
252.89K
+0.28%
J. Goldman & Co., L.P.
220.71K
-8.60%
Bridgeway Capital Management, LLC
188.35K
+2.28%
Boothbay Fund Management, LLC
180.23K
-19.47%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-19

The current risk assessment score of Cumberland Pharmaceuticals Inc is 2.31, ranking 128/158 in the Pharmaceuticals industry. The company's beta value is -0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.78
Change
-0.47
Beta vs S&P 500 index
-0.69
VaR
+6.84%
240-Day Maximum Drawdown
+71.94%
240-Day Volatility
+124.28%

Return

Best Daily Return
60 days
+20.20%
120 days
+20.20%
5 years
+128.64%
Worst Daily Return
60 days
-12.41%
120 days
-15.30%
5 years
-22.73%
Sharpe Ratio
60 days
+2.02
120 days
+1.07
5 years
+0.50

Risk Assessment

Maximum Drawdown
240 days
+71.94%
3 years
+71.94%
5 years
+84.73%
Return-to-Drawdown Ratio
240 days
+1.29
3 years
+0.33
5 years
+0.07
Skewness
240 days
+2.95
3 years
+5.65
5 years
+8.15

Volatility

Realised Volatility
240 days
+124.28%
5 years
+108.96%
Standardised True Range
240 days
+9.07%
5 years
+4.65%
Downside Risk-Adjusted Return
120 days
+164.57%
240 days
+164.57%
Maximum Daily Upside Volatility
60 days
+96.50%
Maximum Daily Downside Volatility
60 days
+55.99%

Liquidity

Average Turnover Rate
60 days
+0.56%
120 days
+0.44%
5 years
--
Turnover Deviation
20 days
-87.14%
60 days
-83.56%
120 days
-87.19%

Peer Comparison

Pharmaceuticals
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
CPIX
6.96 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Cumberland Pharmaceuticals Inc?

The TradingKey Stock Score provides a comprehensive assessment of Cumberland Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Cumberland Pharmaceuticals Inc’s performance and outlook.

How do we generate the financial health score of Cumberland Pharmaceuticals Inc?

To generate the financial health score of Cumberland Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Cumberland Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Cumberland Pharmaceuticals Inc.

How do we generate the company valuation score of Cumberland Pharmaceuticals Inc?

To generate the company valuation score of Cumberland Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Cumberland Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Cumberland Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Cumberland Pharmaceuticals Inc.

How do we generate the earnings forecast score of Cumberland Pharmaceuticals Inc?

To calculate the earnings forecast score of Cumberland Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Cumberland Pharmaceuticals Inc’s future.

How do we generate the price momentum score of Cumberland Pharmaceuticals Inc?

When generating the price momentum score for Cumberland Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Cumberland Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Cumberland Pharmaceuticals Inc.

How do we generate the institutional confidence score of Cumberland Pharmaceuticals Inc?

To generate the institutional confidence score of Cumberland Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Cumberland Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Cumberland Pharmaceuticals Inc.

How do we generate the risk management score of Cumberland Pharmaceuticals Inc?

To assess the risk management score of Cumberland Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Cumberland Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Cumberland Pharmaceuticals Inc.
KeyAI